THE ONE THING
Healthcare turns late-stage: two names hit Crowded or Fading in a single week
By Cathy · Lead Analyst, Fundprints
Abivax, the French biotech whose lead drug is in late-stage trials for ulcerative colitis and Crohn's disease, and Boston Scientific, the global medical-device maker whose cardiovascular and neuro portfolios sit inside hospitals worldwide, both reached late positioning stages this week. Two names crossing that threshold together in one sector is uncommon…
The historical echo — what happened the last time this setup appeared — is in the full memo.
THE STORYLINES
Healthcare sees two late-stage prints in one week: ABVX and BSX
2 names · Healthcare · names in the full memo
ALSO IN THIS EDITION
- The tape — all 10 Prints this week, each with its base rate and why it matters
- For your book — what this week's evidence changes for the names you hold
Read the full memo.
The storylines in full, the historical echo, every Print with its base rate, and what it means for the names you actually own. New edition every week.